March 2, 2023Open Access

First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

The potential benefit observed with triplet therapy must be interpreted with careful accounting for the volume of disease and the choice of doublet comparisons used in the clinical trials. These findings suggest an equipoise to how triplet regimens compare with API doublet combinations and provide direction for future clinical trials.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Riaz et al. (Thu,) studied this question.

synapsesocial.com/papers/69d6d8fb639f29d8dcab369a https://doi.org/https://doi.org/10.1001/jamaoncol.2022.7762

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The role of chemotherapy in metastatic prostate cancer2022 · 9 citations
2Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial2019 · 399 citations
3Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial2013 · 740 citations
4GRADE guidelines: 3. Rating the quality of evidence2011 · 8,199 citations
5Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).2022 · 53 citations

Demander à l'IA

Bookmark

View Full Paper